Articles Tagged With:
-
Glycoprotein IIb/IIIa Receptor Inhibitor Tirofiban for Ischemic Stroke
Glycoprotein IIb/IIIa receptor inhibitors are potent, rapidly acting antiplatelet agents that have been tried in pilot studies to treat acute ischemic stroke, without significant benefit. Tirofiban is fast-acting, highly selective, and has a short half-life that allows bleeding time to return to normal within three hours after administration is stopped. The investigators proposed that this medication may be of benefit in patients with acute ischemic stroke who arrived within 24 hours after stroke onset but are not eligible for thrombolysis or thrombectomy or have progression of stroke symptoms after receiving thrombolysis.
-
Endovascular Thrombectomy for Large Ischemic Core Strokes
Endovascular thrombectomy has been rapidly adopted throughout the world for the treatment of patients with acute ischemic stroke and large vessel occlusion. This approach has achieved strong recommendations in stroke guidelines. However, the trials that form the basis of the recommendations have strict imaging recruitment criteria.
-
Is Dexamethasone Effective in the Treatment of Chronic Subdural Hematomas?
Chronic subdural hematomas are common disorders and may occur after minor trauma or no trauma. For decades, nonsurgical therapies have been tried and proposed, including the use of corticosteroids. Various case series and nonrandomized trials of treatment with corticosteroids have been reported to show benefit, but efficacy of steroid therapy has been uncertain.
-
Decompressive Craniectomy for Acute Subdural Hematoma
There has been longstanding discussion about whether craniectomy results in better outcomes than craniotomy with preservation of the skull for treatment of patients with acute subdural hematomas. This multicenter, international clinical trial was designed to compare the long-term results, benefits, and complications of decompressive craniectomy vs. craniotomy in patients with acute subdural hematomas.
-
Gene Therapy for Leber’s Hereditary Optic Neuropathy Patients: The REFLECT Trial
Gene therapy for Leber’s hereditary optic neuropathy, a mitochondrial genetic disorder, using nuclear deoxyribonucleic acid that is transported into mitochondria, shows promising benefits in the treatment of this disease.
-
Mpox-Associated Neurological Disease
Neurological consequences of mpox (monkeypox) are rare and have not been attributed to direct viral invasion of the central nervous system.
-
Long-Term Outcome for Patients with CIDP
In a careful meta-analysis of published series of treated patients with chronic inflammatory demyelinating polyneuropathy (CIDP), about one-half of patients achieved a good long-term remission with independent function and only about 8% were unable to walk independently.
-
Using Artificial Intelligence to Optimize Aortic Stenosis Echocardiographic Surveillance
A machine learning model to predict the frequency of echocardiographic exams in patients with mild-to-moderate aortic stenosis necessary to accurately detect the onset of severe stenosis performed with a high degree of accuracy would reduce the number of unnecessary echocardiograms specified by current guidelines.
-
The Safety of Catheter Ablation for Atrial Fibrillation
A meta-analysis of randomized, controlled studies of first catheter ablation for atrial fibrillation showed complication rates are low and have declined over time. Mortality rates are very low and have remain unchanged over the same period.
-
Absorb Stent Disappoints Again in 5-Year Data
In this long-term follow up of the ABSORB IV trial, the five-year rate of target lesion failure was significantly higher with the everolimus-eluting bioabsorbable scaffold compared with its metallic counterpart, despite strict adherence to recommended implantation techniques.